Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
About Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to develop locally delivered, extended-release pharmaceuticals that address significant unmet medical needs. The company is headquartered in Victoria, British Columbia, and is publicly traded on both the Toronto Stock Exchange (TSX: EPRX) and NASDAQ (EPRX).
Core Business Areas
Eupraxia focuses on precision drug delivery systems designed to optimize therapeutic outcomes by targeting specific tissues with minimal systemic exposure. Its lead product candidates include:
- EP-104IAR: A long-acting formulation for the treatment of pain associated with osteoarthritis of the knee. This product has demonstrated clinically significant and durable pain relief in Phase 2 trials, with a strong safety profile and minimal systemic side effects.
- EP-104GI: A novel treatment for eosinophilic esophagitis (EoE), an inflammatory condition of the esophagus. The RESOLVE Phase 1b/2a trial has shown promising results, including improved tissue health and symptom reduction, without significant adverse effects.
Proprietary Technology: DiffuSphere™
Eupraxia's innovative DiffuSphere™ technology is a polymer-based microsphere platform designed to deliver drugs in a controlled, localized, and extended-release manner. This technology ensures a stable pharmacokinetic profile, avoiding the peaks and troughs commonly associated with conventional drug delivery systems. By maintaining high drug concentrations in target tissues while minimizing systemic exposure, DiffuSphere™ enhances efficacy and reduces the risk of adverse events.
Applications of DiffuSphere™ extend beyond osteoarthritis and EoE, with potential uses in oncology, infectious diseases, and other inflammatory conditions. The platform's versatility has been demonstrated in preclinical and clinical studies across various anatomical locations, including intra-articular, intra-esophageal, and subcutaneous applications.
Clinical Development and Pipeline
Eupraxia is actively advancing its clinical programs:
- SPRINGBOARD Trial: A Phase 2b study evaluating EP-104IAR for knee osteoarthritis pain, which met its primary endpoint and three of four secondary endpoints. The results were published in The Lancet Rheumatology, highlighting the product's potential to set a new standard of care.
- RESOLVE Trial: A Phase 1b/2a study for EP-104GI in EoE, demonstrating a strong dose-response relationship and significant improvements in patient-reported symptoms and histological outcomes.
In addition to these lead programs, Eupraxia is developing a pipeline of earlier-stage formulations targeting other inflammatory joint indications and oncology, with a focus on improving the safety and efficacy of existing therapies.
Market Significance
Eupraxia operates in a competitive biotechnology landscape, addressing growing markets such as osteoarthritis, which affects over 30 million people in the U.S., and eosinophilic esophagitis, a rapidly increasing condition impacting over 450,000 individuals in the U.S. alone. The company's targeted, long-acting therapies offer a compelling alternative to traditional treatments, with the potential to improve patient outcomes and reduce healthcare costs.
Competitive Advantages
Eupraxia's differentiation lies in its ability to:
- Deliver drugs locally with precision and extended duration, minimizing systemic side effects.
- Address high unmet medical needs with innovative formulations.
- Leverage a versatile platform technology applicable across multiple therapeutic areas.
These strengths position Eupraxia as a key player in the biotechnology sector, with the potential to transform treatment paradigms in its target markets.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company, has announced its participation in the United European Gastroenterology (UEG) Week 2024 in Vienna, Austria, from October 12-15, 2024. The company will present a poster featuring data from the RESOLVE trial, a Phase 1b/2a dose-escalation study of EP-104GI for Eosinophilic Esophagitis.
The presentation details include:
- Poster Number: PP0584
- Title: Results from Dose Escalation in RESOLVE, an Ongoing Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
- Topic: Oesophageal, gastric and duodenal
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) has announced key appointments to strengthen its senior management team. Dr. Amanda Malone, co-founder and former Chief Scientific Officer, has been promoted to Chief Operating and Scientific Officer. Dr. Rahul Sarugaser joins as Executive Vice President of Corporate Development.
Dr. Malone, who co-founded Eupraxia in 2012, has been instrumental in developing the company's DiffuSphere™ technology and leading successful clinical trials. Dr. Sarugaser brings 20 years of experience in capital markets and healthcare, most recently as Managing Director of Equity Research at Raymond James.
Eupraxia is advancing its DiffuSphere™ technology for targeted drug delivery in areas with high unmet medical need. The company's lead product, EP-104GI, is in a Phase 1b/2a trial for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial of EP-104IAR for knee osteoarthritis pain.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced its participation in the 20th International Symposium on Digestive Endoscopy (ISDE) World Congress for Esophageal Diseases in Edinburgh, Scotland, from September 22-24, 2024. The company will present a poster titled 'Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis'.
The presentation, scheduled for September 23, 2024, from 12:00 PM to 1:45 PM BST, will showcase data from cohorts one through four of the RESOLVE trial. It falls under the 'Benign Disease' theme and has been assigned paper number 265. Eupraxia, a clinical-stage biotechnology company, utilizes its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet needs.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating eosinophilic esophagitis (EoE). Key findings include:
- 10 of 11 evaluable patients in the first four cohorts experienced reduced symptom scores at 12 weeks
- The fourth cohort showed the greatest percentage change in histology scores to date
- No serious adverse events reported across all four fully-dosed cohorts
The fourth cohort data showed:
- 45% mean reduction in symptom scores at 12 weeks
- 39% mean reduction in histology composite stage scores
- 67% mean reduction in peak eosinophil counts
These results are comparable to currently approved EoE therapies. The company remains optimistic about further improvements as the trial progresses towards optimal dosing.
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. The company's presentation is scheduled for 8:00 a.m. ET on Monday, September 9, 2024. Interested parties can view the presentation via a provided link or on the company's website.
Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release products using its proprietary DiffuSphere™ technology. The company's lead product, EP-104GI, is currently in a Phase 1b/2a trial (RESOLVE) for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial (SPRINGBOARD) of EP-104IAR for osteoarthritis knee pain. The company is also developing a pipeline of long-acting formulations for inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) reported its Q2 2024 financial results. Key highlights include:
- Positive progress in the eosinophilic esophagitis (EoE) clinical program with EP-104GI
- Presentations on EP-104IAR for knee osteoarthritis (OA) at medical meetings
- Net loss of $6.1 million, down from $9.5 million in Q2 2023
- Cash position of $23.3 million as of June 30, 2024
- New C$12 million convertible debt facility announced post-quarter end
The company anticipates reporting new data from the RESOLVE study soon and plans to engage with the FDA in Q4 2024 regarding the EP-104GI program.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced a new C$12 million convertible debt facility with Yabema Capital and other current shareholders. The facility is available for drawdown within 120 days, subject to the release of the existing SVB Facility. The conversion price is set at C$4.84375 per Common Share.
The company has also provided an update on its existing SVB Facility, which matured on June 21, 2024, with a total liability of C$12 million. Eupraxia has fully discharged C$6 million to SVB Innovation Credit Fund and is in discussions for the remaining settlement. The company's cash reserves will be reduced by up to C$12 million to settle this debt.
Including the new convertible debt facility, Eupraxia anticipates having sufficient cash to fund operations until the second quarter of 2025.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announces that Dr. Amanda Malone, Chief Operating and Scientific Officer, will present at the Controlled Release Society 2024 Annual Meeting and Expo in Bologna, Italy, from July 8-12, 2024.
The presentation, titled 'EP-104, a novel microparticle formulation achieving extended-release of fluticasone propionate,' will occur on July 10, 2024, from 9:00 AM to 11:00 AM CEST (3:00 AM to 5:00 AM ET) during the 'Long-Acting Drug Delivery Formulations - Session #2'. The presentation can be accessed online at Eupraxia's website.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX), a clinical-stage biotech firm utilizing its proprietary DiffuSphere™ technology, announced that its CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar titled, "Exploring The Rapid Rise of Osteoarthritis." The event is set for July 9, 2024, at 8:30 am PT / 11:30 am ET. Osteoarthritis is a leading cause of disability among older adults, with knee OA affecting over 30 million people in the U.S. alone. Registration for this public event is open, and questions for Dr. Helliwell can be submitted via Tribe Public’s email or ZOOM chat during the event. John F. Heerdink, Jr. from Tribe Public will moderate the session.
Eupraxia Pharmaceuticals, a clinical-stage biotech firm, announced the results of its Annual General and Special Meeting of Shareholders held on June 6, 2024. All six board nominees were elected, with votes overwhelmingly in favor. KPMG LLP was appointed as the auditor, and several business items, including stock option plans and potential share consolidations, were approved. Eupraxia focuses on extended-release drug delivery through its DiffuSphere™ technology. The company recently completed a successful Phase 2b trial for osteoarthritis and is expanding into gastrointestinal treatments with ongoing trials.
FAQ
What is the current stock price of Eupraxia Pharmac (EPRX)?
What is the market cap of Eupraxia Pharmac (EPRX)?
What does Eupraxia Pharmaceuticals specialize in?
What is DiffuSphere™ technology?
What are Eupraxia's lead product candidates?
What makes Eupraxia's approach unique?
What markets does Eupraxia target?
What clinical trials has Eupraxia completed?
What are the potential applications of DiffuSphere™ technology?
How does Eupraxia differentiate itself from competitors?
What is the significance of Eupraxia's clinical data?
What regulatory challenges does Eupraxia face?
